A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy

This publication has 13 references indexed in Scilit:

• A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial)
  Leukemia & Lymphoma, 2003
• Complications of Radiation Therapy for Head and Neck Cancers
  Cancer Nursing, 2002
• Iseganan HCl: a novel antimicrobial agent
  Expert Opinion on Investigational Drugs, 2002
• A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
  Published by Elsevier ,2000
• Protegrins: new antibiotics of mammalian origin
  Expert Opinion on Investigational Drugs, 2000
• Toxicity in head and neck cancer: a review of trends and issues
  International Journal of Radiation Oncology*Biology*Physics, 2000
• Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues
  Biopolymers, 2000
• Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity
  Oral Oncology, 1998
• A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis
  Cancer, 1997
• The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial
  British Journal of Cancer, 1996